Combination therapy of disseminated Fusarium oxysporum infection with terbinafine and amphotericin B

被引:41
作者
Rothe, A
Seibold, M
Hoppe, T
Seifert, H
Engert, A
Caspar, C
Karthaus, M
Fätkenheuer, G
Bethe, U
Tintelnot, K
Cornely, OA
机构
[1] Univ Cologne, Innere Med Klin 1, D-50931 Cologne, Germany
[2] Robert Koch Inst, D-13353 Berlin, Germany
[3] Univ Cologne, Inst Med Mikrobiol Immunol & Hyg, D-50935 Cologne, Germany
[4] Univ Cologne, Klin & Poliklin Dermatol & Venerol, D-50935 Cologne, Germany
[5] Ev Johannes Krankenhaus, Med Klin 2, D-33611 Bielefeld, Germany
关键词
disseminated fusariosis; Fusarium oxysporum; febrile neutropenia; fungemia; skin lesions; combination therapy;
D O I
10.1007/s00277-003-0795-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A case of disseminated infection with Fusarium oxysporum following chemotherapy of acute myelogenous leukemia is reported. Antifungal treatment was successful with a 13-day course of oral terbinafine 250 mg t.i.d. in combination with amphotericin B deoxycholate 1.0-1.5 mg/kg qd and subsequently intravenous liposomal amphotericin B 5 mg/kg qd. Preceding monotherapy with amphotericin B deoxycholate 1.0-1.5 mg/kg qd had not stopped the progression of infection. The combination therapy described here represents a novel approach to the treatment of Fusarium spp. in the immunocompromised host in whom Fusarium spp. are known to cause disseminated infection with high mortality.
引用
收藏
页码:394 / 397
页数:4
相关论文
共 17 条
[1]   Fusariosis associated with pathogenic Fusarium species colonization of a hospital water system:: A new paradigm for the epidemiology of opportunistic mold infections [J].
Anaissie, EJ ;
Kuchar, RT ;
Rex, JH ;
Francesconi, A ;
Kasai, M ;
Müller, FMC ;
Lozano-Chiu, M ;
Summerbell, RC ;
Dignani, MC ;
Chanock, SJ ;
Walsh, TJ .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (11) :1871-1878
[2]   In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. [J].
Arikan, S ;
Lozano-Chiu, M ;
Paetznick, V ;
Rex, JH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (01) :245-247
[3]   Fusarium, a significant emerging pathogen in patients with hematologic malignancy: Ten years' experience at a cancer center and implications for management [J].
Boutati, EI ;
Anaissie, EJ .
BLOOD, 1997, 90 (03) :999-1008
[4]   New antifungal agents and preparations [J].
De Pauw, BE .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2000, 16 (02) :147-150
[5]   In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds [J].
DelPoeta, M ;
Schell, WA ;
Perfect, JR .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (08) :1835-1836
[6]   In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens [J].
Espinel-Ingroff, A .
JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (01) :198-202
[7]   Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts [J].
Espinel-Ingroff, A .
JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (10) :2950-2956
[8]   OPPORTUNISTIC FUSARIAL INFECTIONS IN HUMANS [J].
GUARRO, J ;
GENE, J .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1995, 14 (09) :741-754
[9]   Identification of Fusarium species involved in human infections by 28S rRNA gene sequencing [J].
Hennequin, C ;
Abachin, E ;
Symoens, F ;
Lavarde, V ;
Reboux, C ;
Nolard, N ;
Berche, P .
JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (11) :3586-3589
[10]   Voriconazole: A new triazole antifungal agent [J].
Johnson, LB ;
Kauffman, CA .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (05) :630-637